A novel glutaminase inhibitor CB-839, may provide a survival benefit in combination with cabozantinib (Cabometyx) by cutting off the energy supply to tumor cells in patients with metastatic renal cell carcinoma.
Original Article: Agent That Starves Tumor Cells May Improve Survival in Metastatic RCC